Erlotinib
- Generic Name
- Erlotinib
- Brand Names
- Tarceva
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23N3O4
- CAS Number
- 183321-74-6
- Unique Ingredient Identifier
- J4T82NDH7E
- Background
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion...
- Indication
Erlotinib is indicated for:
The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy.
- Associated Conditions
- Locally Advanced Pancreatic Cancer (LAPC), Metastatic Non-Small Cell Lung Cancer, Pancreatic Metastatic Cancer, Unresectable Pancreatic Cancer
- Associated Therapies
- -
Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar
- First Posted Date
- 2007-05-22
- Last Posted Date
- 2015-05-07
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 41
- Registration Number
- NCT00476476
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Women and Infants Hospital of Rhode Island, Providence, Rhode Island, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-05-14
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- British Columbia Cancer Agency
- Target Recruit Count
- 150
- Registration Number
- NCT00473083
- Locations
- 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇨🇦Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦BC Cancer Agency Vancouver Centre, Vancouver, British Columbia, Canada
Surgery for Early Lung Cancer With Preoperative Erlotinib (Tarceva): A Clinical Phase II Trial (SELECT)
- First Posted Date
- 2007-04-19
- Last Posted Date
- 2018-02-23
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 25
- Registration Number
- NCT00462995
- Locations
- 🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada
🇨🇦Princess Margaret Hospital, Toronto, Ontario, Canada
A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship Between Skin Toxicity and Survival
- First Posted Date
- 2007-04-18
- Last Posted Date
- 2015-10-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 153
- Registration Number
- NCT00461708
A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone
- Conditions
- Interventions
- First Posted Date
- 2007-04-06
- Last Posted Date
- 2013-10-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 960
- Registration Number
- NCT00457392
- Locations
- 🇬🇧
Pfizer Investigational Site, Yeovil, Somerset, United Kingdom
Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy
- First Posted Date
- 2007-04-05
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 248
- Registration Number
- NCT00456833
- Locations
- 🇷🇺
Novartis Investigative Site, Moscow, Russian Federation
A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-03-27
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 65
- Registration Number
- NCT00452413
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lubbock, Texas, United States
Erlotinib as First-line Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) for Patients Unfit for Chemotherapy
- First Posted Date
- 2007-03-26
- Last Posted Date
- 2014-12-11
- Lead Sponsor
- Rigshospitalet, Denmark
- Target Recruit Count
- 24
- Registration Number
- NCT00452075
- Locations
- 🇩🇰
Department of Oncology, Odense University Hospital, Odense, Denmark
🇩🇰Department of Oncology, Rigshospitalet, Copenhagen, Denmark
🇩🇰Department of Oncology, Århus University Hospital, Århus, Denmark
Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer
- Conditions
- First Posted Date
- 2007-03-16
- Last Posted Date
- 2010-02-02
- Lead Sponsor
- Henry Ford Health System
- Target Recruit Count
- 6
- Registration Number
- NCT00448240
Study of Pemetrexed Versus Pemetrexed Plus Erlotinib as Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2007-03-13
- Last Posted Date
- 2011-10-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 204
- Registration Number
- NCT00447057
- Locations
- 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Solna, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.